Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • Pulmonology
  • Pulmonology News
  • Efzofitimod Fails to...

Efzofitimod Fails to Reduce Steroid Use in Pulmonary Sarcoidosis but Improves Quality of Life: Study

Written By : Medha Baranwal ,Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2026-11-17T19:00:00+05:30  |  Updated On 18 Nov 2026 12:10 PM IST
Efzofitimod Fails to Reduce Steroid Use in Pulmonary Sarcoidosis but Improves Quality of Life: Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: Efzofitimod was safe and well tolerated in patients with pulmonary sarcoidosis but did not significantly reduce corticosteroid doses compared with placebo at 48 weeks. However, structured steroid-tapering protocols enabled many patients to maintain substantially lower steroid doses for up to 32 weeks. Efzofitimod also improved patient-reported outcomes, including lung-related quality of life, general health, and fatigue.

Pulmonary sarcoidosis is an inflammatory disease in which immune cells form granulomas in the lungs, potentially affecting respiratory function and quality of life. Oral corticosteroids remain the standard treatment, but prolonged use can cause significant adverse effects and affect patients' overall well-being. Efzofitimod is a novel immunomodulatory fusion protein that targets the neuropilin-2 receptor and is being investigated as a potential steroid-sparing treatment.
To evaluate its efficacy and safety, Daniel A. Culver, DO, from the Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Ohio, USA, and colleagues conducted the EFZO-FIT trial, published in The Lancet Respiratory Medicine.
The phase 3 trial was conducted across 85 centres in nine countries and included adults aged 18–75 years with pulmonary sarcoidosis requiring treatment. A total of 268 participants were randomised to receive monthly intravenous efzofitimod (3 mg/kg or 5 mg/kg) or placebo for 48 weeks. All participants followed a 12-week corticosteroid tapering programme, targeting complete withdrawal.
Of the 268 participants, 264 were included in the final analysis. Their mean age was 53.8 years, and 57% were men. Average daily corticosteroid doses declined from 10.7 mg at baseline to 2.9 mg at week 48.
However, corticosteroid reduction did not differ significantly between the efzofitimod and placebo groups. The findings revealed:
  • No significant steroid-sparing benefit: The placebo-adjusted change in daily corticosteroid dose was 0.02 mg in the 3 mg/kg efzofitimod group and −0.73 mg in the 5 mg/kg group, with neither difference reaching statistical significance.
  • Sustained steroid reduction: Despite the absence of a significant treatment advantage, the structured tapering programme allowed many participants to maintain lower corticosteroid doses for up to 32 weeks.
  • Improved patient-reported outcomes: Efzofitimod was associated with improvements in lung-related quality of life, general health and fatigue.
  • Comparable serious adverse events: The proportion of patients experiencing serious treatment-emergent adverse events was similar across the three groups.
  • Mostly mild adverse effects: Headache, sinusitis, wheezing, and increased aspartate aminotransferase levels were reported more frequently in the efzofitimod groups. Most adverse events were mild to moderate.
  • Deaths during the trial: Two participants in the 3 mg/kg group died, one from respiratory failure and another from complications involving a pre-existing inguinal hernia. Neither death was considered related to the study treatment.
The researchers concluded that although efzofitimod demonstrated a favourable tolerability profile, it did not significantly reduce corticosteroid requirements compared with placebo at 48 weeks. However, the substantial steroid reduction achieved across treatment groups suggests that structured tapering may allow many patients with pulmonary sarcoidosis to reduce their long-term corticosteroid exposure.
Reference:
Culver, D. A., Bonella, F., Gupta, R., Spagnolo, P., Veltkamp, M., Cameli, P., Restrepo, C. I., Frye, B. C., Kameda, M., Cifrián-Martínez, J., Ali, H., Aryal, S., Carmona, E. M., Nunes, H., Obi, O. N., Hart, S. P., Sellarés, J., Azuma, A., Grutters, J. C., . . . Baughman, R. P. (2026). Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(26)00283-3
The Lancet Respiratory MedicineEfzofitimodpulmonary sarcoidosisEFZO-FIT trial
Source : The Lancet Respiratory Medicine

Medical Survey

Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    View All

    Journal Club Today

    Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

    Scientists Discover Surprising Role of Vitamin B12 in Correcting Genetic Disorder-Related Defects

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok